Lifeboat Foundation

The findings, published in Nature Communications, could have important implications for human health: minis have been found at every type of synapse studied so far, and defects in miniature neurotransmission have been linked to range of neurodevelopmental disorders in children. Figuring out how a reduction in miniature neurotransmission changes the structure of synapses, and how that in turn affects behavior, could help to better understand neurodegenerative disorders and other brain conditions.

Summary: Study reveals how miniature release events help to keep neurons intact and preserve motor neuron function in aging insects.

Source: EPFL

Continue reading “Brain ‘Noise’ Keeps Nerve Connections Young” »

Replacing Aging — Dr. Jean M. Hebert, Ph.D. Albert Einstein College of Medicine.

Dr. Jean M. Hebert, Ph.D. (https://einsteinmed.org/faculty/9069/jean-hebert/) is Professor in the Department of Genetics and in the Dominick P. Purpura Department of Neuroscience, at Albert Einstein College of Medicine.

Continue reading “Dr. Jean M. Hebert, Ph.D. — Replacing Aging — Albert Einstein College of Medicine” »

Pulsechain has raised $25000, 000 for antiaging medical research after 5 days of a 14 day fundraiser. You must follow the SENS.org PulseChain instructions. Sacrifices to SENS.org during the sacrifice phase earn 25% less points compared to sacrifices at Pulse.info. SENS.org can also accept stocks and bank wires. Once the sacrifice phase is over, the total sacrifice points for each sacrificer’s address’s points (at the same metamask address) are totaled up across all the supported chains and the SENS.org report. This creates a list of sacrificers ranked by total points from largest to smallest.

SENS Research Foundation has been working to develop, promote, and ensure widespread access to therapies that cure and prevent the diseases and disabilities of aging by comprehensively repairing the damage that builds up in our bodies over time. SENS is redefining the way the world researches and treats age-related ill health, while inspiring the next generation of biomedical scientists. Aubrey dr Grey and SENS have been the leading proponents of repairing aging damage to reverse aging effects. They have been leading the research effort for aging damage repair for over 20 years.

Continue reading “$25 Million Raised for SENS Antiaging Research Via Pulsechain Crypto Drive” »

Encouraging Mid Trial data update! Great to know Dr. Katcher is applying for IRB approval for their human clinical trial for E5.

In this video we provide an update on Dr. Katcher’s experiment where he is treating rats with E5 (formerly called Elixer) on a regular schedule to see how long they will live for. Dr Katcher’s team have kindly provided some intermediate updates that we share in the video.
0:00 — 00:50 Introduction.
00:51 — 04:02 Project Background/Overview.
04:03 — Project Update.

Continue reading “Reverse Aging of 54% Study Extension — Dr. Harold Katcher’s E5 Project Update July 2021” »

NYU Abu Dhabi (NYUAD) researchers have uncovered a code that sets the genome of the liver to account for the remarkable ability for this organ to regenerate. This finding offers new insight into how the specific genes that promote regeneration can be activated when part of the liver is removed. These findings have the potential to inform the development of a new form of regenerative medicine that could help non-regenerative organs regrow in mice and humans.

While other animals can regenerate most organs, humans, mice, and other mammals can only regenerate their liver in response to an injury or when a piece is removed. NYUAD researchers hypothesized that the genes that drive regeneration in the liver would be controlled by a specific code that allows them to be activated in response to injury or resection. They home in on the epigenome, which is the modifications on the DNA that alter the gene expression, as opposed to changing the genetic code itself.

Using a mouse liver model, the team of NYUAD researchers, led by Professor of Biology Kirsten Sadler Edepli, identified the elements of the epigenetic code present in quiescent liver cells—cells that are currently not replicating but have the ability to proliferate under the right conditions—that activate specific genes to regenerate. Genes involved in liver cell proliferation are silenced in livers that are not regenerating, but the surprising finding was that they reside in parts of the genome where most genes are active. The researchers found that these pro-regenerative genes were marked with a specific modification—H3K27me3. During regeneration, H3K27me3 is depleted from these genes, enabling their dynamic expression and driving proliferation.

A new $7.9 million seed round boosts Butlr Technologies’ ability to apply its real-time people-sensing technology beyond commercial real estate and retail uses to monitor falls and other movements for active seniors who are aging in place.

Hyperplane led the round, with Founder Collective, Union Labs, 500 Startups, SOSV, E14 Fund, Tectonic Ventures, Scott Belsky, Chad Laurans and Sunny Vu participating.

The new funding comes one year after the Burlingame, California-based proptech company raised $1.2 million in convertible notes, which is included in the $7.9 million. It is developing a platform and Heatic sensors that detect someone’s body heat anonymously to determine occupancy, headcount and activity.

Interested in living longer? You are probably going to get TPE at some point. The Conboys are looking for funding for human trials to produce a product in 3–4 years. Here we have infor on what it is and how it works plus actual human results to date (starting at 10 minutes).

In Part III, Dr Kiprov, discusses the history of moving from the Conboy’s experiments in the lab to the process used in the clinic and reasons for the choices made. He also covers the benefits that he has seen with plasma exchange in the clinic.

Continue reading “Plasma Dilution Potential Benefits & Real Cases Part III | Dr Dobri Kiprov Interview Series” »

A potentially life-saving treatment for heart attack victims has been discovered from a very unlikely source — the venom of one of the world’s deadliest spiders.

A drug candidate developed from a molecule found in the venom of the Fraser Island (K’gari) funnel web spider can prevent damage caused by a heart attack and extend the life of donor hearts used for organ transplants. The discovery was made by a team led by Dr Nathan Palpant and Professor Glenn King from The University of Queensland (UQ) and Professor Peter Macdonald from the Victor Chang Cardiac Research Institute.

Dr Palpant, from UQ’s Institute for Molecular Bioscience (IMB), said the drug candidate worked by stopping a ‘death signal’ sent from the heart in the wake of an attack.

Timestamps:

0:00 How the Rose lab more than doubled the lifespan of Drosophila.
17:20 Use of machine learning (ML) and multi-‘omics to characterize aging, and use of ML to develop interventions.
37:04 Adherence to an ancestral diet in Drosophila extends healthspan relative to their evolutionary recent diet.
40:35 The importance of measuring objective markers of health to determine if one’s diet is best for them.
44:04 Does aging stop, and use of biomarker testing to help decipher/optimize that.
53:33 The importance of characterizing aging for both Drosophila and its co-associated microbiome.
1:00:35 Why a massive, wide-scale, Manhattan-project approach for increasing human lifespan is necessary.